Transgene Biotek Limited has filed a mandatory compliance certificate with the Bombay Stock Exchange (BSE) confirming proper maintenance of its share transfer facility as required under securities regulations.

Regulatory Compliance Filing

The company submitted the compliance certificate on April 13, 2026, addressed to the General Manager of BSE's Listing Compliance Department. The filing was made pursuant to Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Share Transfer Agent Details

The certificate confirms that Transgene Biotek Limited maintains both physical and electronic share transfer facilities through its appointed registrar and share transfer agent, Bigshare Services Private Limited. This arrangement ensures proper handling of share transfer activities for the company's shareholders.

Compliance Significance

The filing represents routine regulatory compliance for listed companies under SEBI LODR Regulations. The certificate was duly signed by authorized representatives from both Transgene Biotek Limited and Bigshare Services Private Limited, confirming the ongoing maintenance of share transfer facilities as mandated by securities regulations.

This compliance filing demonstrates the company's adherence to mandatory disclosure requirements and ensures transparency in share transfer operations for investors and regulatory authorities.

Transgene Biotek Limited has announced its unaudited standalone and consolidated financial results for the quarter ended December 31, 2025, revealing significant operational challenges with widening losses and declining revenue performance.

Financial Performance Overview

The company reported a substantial increase in net losses for the third quarter of FY26, with both standalone and consolidated results showing identical figures due to minimal subsidiary operations.

Revenue and Income Analysis

The company's revenue from operations declined to ₹5.45 lakhs in Q3 FY26 from ₹7.65 lakhs in Q3 FY25, representing a decrease of 28.76%. The decline was more pronounced in total income, which fell from ₹12.03 lakhs to ₹5.45 lakhs, primarily due to the absence of other income that contributed ₹4.38 lakhs in the previous year quarter.

Expense Structure and Cost Pressures

Total expenses more than doubled to ₹42.82 lakhs in Q3 FY26 from ₹20.93 lakhs in Q3 FY25. The most significant contributor to this increase was finance costs, which surged to ₹27.35 lakhs from ₹1.73 lakhs in the corresponding quarter of the previous year.

Nine-Month Performance

For the nine-month period ended December 31, 2025, the company's performance deteriorated significantly. Revenue from operations declined to ₹15.68 lakhs from ₹18.42 lakhs in the corresponding period of the previous year. The company reported a net loss of ₹119.59 lakhs for the nine-month period compared to a profit of ₹3.70 lakhs in the previous year.

Other Expenses Breakdown

The detailed breakdown of other expenses for Q3 FY26 shows legal and professional charges as the largest component at ₹3.24 lakhs, followed by PCB renewal costs of ₹2.87 lakhs. Other significant expenses included contractual expenses of ₹0.27 lakhs and advertisement costs of ₹0.22 lakhs.

Corporate Governance and Legal Matters

The company continues to deal with several ongoing legal proceedings. The matter in SAT has a hearing scheduled for February 24, 2026, while the hearing at the Appellate Tribunal, New Delhi is set for April 14, 2026. Additionally, the appeal at NCLT Hyderabad bench is scheduled for March 3, 2026. The company reported no complaints pending or received during the quarter.

Board Approval and Audit

The financial results were approved by the Board of Directors at a meeting held on February 13, 2026, which commenced at 11:00 a.m. and concluded at 11:45 a.m. The results underwent limited review by M/s Vasavi & Co, Chartered Accountants, who provided unqualified review reports for both standalone and consolidated financial statements.